Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Hepatocellular Carcinoma
Clinical trial register · China

Hepatocellular Carcinoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 07 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Guangzhou 44 Beijing 38 Shanghai 26 Fuzhou 20 Hangzhou 18
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou44 Beijing38 Shanghai26 Fuzhou20 Hangzhou18
All 57 locations
Target enrolment
to

Hepatocellular Carcinoma trials in China

154 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
West China Hospital
Not applicable
60
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai
2026-12-01
Not yet open
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
690
Nanjing, Shanghai
2026-11
Not yet open
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
560
Harbin, Shanghai
2026-10-08
Not yet open
Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
NCT07880106Lung Cancer Non-small Cell, Colorectal Cancer, Stomach Cancer, Hepatocellular Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
2,000
Shanwei
2026-10-01
Recruiting
Anhui Provincial Hospital
Phase 2
60
Hefei
2026-09-16
Not yet open
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3
600
Nanjing
2026-09
Recruiting
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
NCT07760012Melanoma (Skin Cancer), Hepatocellular Carcinoma, Lung Cancer, Breast Cancer
Peking University Third Hospital
Not applicable
50
Beijing
2026-08-13
Not yet open
YMN-A02 for Advanced Primary Hepatocellular Carcinoma.
NCT07580261Hepatocellular Carcinoma
West China Hospital
Phase 1
10
Chengdu
2026-07-30
Recruiting
Beijing Municipal Administration of Hospitals
Observational
40
Beijing
2026-06-30
Not yet open
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
20
Guangzhou
2026-06-22
Recruiting
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
NCT07623369Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer
Huahui Health
Phase 1
299
Jinan
2026-06-11
Recruiting
Binkui Li
Phase 3
300
Guangzhou
2026-05-15
Not yet open
Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
NCT07558200Solid Tumors, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1
138
Shanghai
2026-05-15
Recruiting
Lepu Biopharma Co., Ltd.
Phase 1/2
160
Beijing, Fuzhou, Zhengzhou, Nanjing, Tianjin, Lishui
2026-04-08
Not yet open
Ningbo No.2 Hospital
Early Phase 1
156
Hangzhou, Ningbo
2026-03-31
Recruiting
Adjuvant TACE in HCC With High-risk Recurrence Factors
NCT07417397Hepatocellular Carcinoma, Adjuvant, Transarterial Chemoembolization
Guangxi Medical University
Phase 3
442
Nanning
2026-02-01
Not yet open
Ningbo Medical Center Lihuili Hospital
Observational
300
Ningbo
2026-01-25
Recruiting
Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
NCT07324824Hepatocellular Carcinoma, Neoadjuvant Therapy, Sintilimab, Bevacizimab
Sun Yat-sen University
Phase 2
37
Guangzhou
2026-01-14
Not yet open
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
68
Chengdu
2026-01-10
Recruiting
Peking Union Medical College Hospital
Phase 2
158
Beijing, Nanjing, Xuzhou
2025-12-24
Active, closed
AI Multimodal Model for Liver Cancer Diagnosis and Prognosis
NCT07658586Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma (Icc)
Guangxi Medical University
Observational
600
Nanning
2025-12-01
Recruiting
Sir Run Run Shaw Hospital
Not applicable
33
Hangzhou
2025-12-01
By invitation
Fujian Provincial Hospital
Observational
729
Fuzhou
2025-12-01
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
300
Wuhan
2025-11-01
Recruiting
Fudan University
Not applicable
120
Shanghai
2025-10-15
Not yet open
Xuhua Duan
Observational
118
Guiyang, Haikou, Kaifeng, Luohe, Luoyang, Nanyang, Shangqiu, Zhoukou
2025-10-10
Recruiting
JMT106 Injection in the Treatment of Advanced Solid Tumors
NCT07275073Advanced Solid Tumor, Lung Squamous Cell Carcinoma, Hepatocellular Carcinoma
Shanghai JMT-Bio Inc.
Phase 1
200
Zhejiang
2025-09-25
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
35
Tianjin
2025-09-10
Recruiting
Fudan University
Observational
50
Shanghai
2025-08-15
Not yet open
The First Affiliated Hospital with Nanjing Medical University
Phase 2
48
Nanjing
2025-08-11
Active, closed
AstraZeneca
Phase 2
114
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing
2025-08-05
Recruiting
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases
NCT07062055Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Oligometastases, Radiotherapy
Shandong Cancer Hospital and Institute
Phase 2
54
Jinan
2025-07-25
Recruiting
Chinese PLA General Hospital
Phase 1
25
Beijing
2025-06-20
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
72
Hefei, Beijing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-05-29
Recruiting
AstraZeneca
Phase 3
1,220
Beijing, Changchun, Changsha, Chengdu, Chifeng, Chongqing, Deyang, Fuzhou
2025-05-06
Recruiting
Textbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma
NCT06950827Hepatocellular Carcinoma, Hepatectomy, Laparoscopic Hepatectomy
West China Hospital
Observational
400
Chengdu
2025-04-05
Recruiting
AstraZeneca
Phase 1/2
304
Chengdu, Guangzhou, Harbin, Shanghai
2025-03-27
Not yet open
Xuhua Duan
Observational
59
Dengzhou, Jiaozuo, Kaifeng, Luoyang, Shangqiu, Zhengzhou, Zhoukou
2025-03-01
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
60
Shijiazhuang
2025-03-01
Recruiting
Bayer
Phase 1
148
Xuhui, Fujian, Wuhan
2025-02-28
Not yet open
Chinese PLA General Hospital
Observational
300
Beijing
2025-01-30
Recruiting
TACE Combined Surgery for the Resectable Huge HCC
NCT06898398Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer, Surgery
Sun Yat-sen University
Observational
326
Beijing
2025-01-01
Not yet open
Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma
NCT06708650Hepatocellular Carcinoma, Radiotherapy, PD-1 Inhibitors
Guiping People's Hospital
Not applicable
50
Guiping
2025-01-01
Recruiting
Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
NCT06446154Hepatocellular Carcinoma, Immune Checkpoint Inhibitors, Anti-angiogenic Therapy, Second-line Treatment
Sun Yat-sen University
Phase 2
36
Guangzhou
2024-12-27
Recruiting
TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma
NCT06740370Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Anti-PD1 Antibody, Lenvatinib
Sun Yat-sen University
Not applicable
32
Beijing
2024-12-13
Recruiting
HAIC Compared With TACE in Huge Hepatocellular Carcinoma
NCT06641713Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer
Sun Yat-sen University
Observational
664
Beijing
2024-10-01
Recruiting
TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
NCT06622031Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Systemic Therapy
Sun Yat-sen University
Not applicable
42
Beijing
2024-10-01
Recruiting
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
NCT06609876Hepatocellular Carcinoma, Microwave Ablation, Donafenib, Recurrent Tumor
Sun Yat-sen University
Not applicable
108
Beijing
2024-10-01
Active, closed
Shanghai AbelZeta Ltd.
Phase 1/2
121
Shanghai, Hanzhou
2024-09-30
Recruiting
Fujian Provincial Hospital
Observational
20
Fuzhou, Xiamen, Zhangzhou
2024-09-30
Recruiting
Akeso
Phase 1/2
280
Beijing, Jinan
2024-09-24
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
100
Hangzhou
2024-09-01
Recruiting
Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC
NCT06467799Hepatocellular Carcinoma, Beyond Milan Criteria
Sun Yat-sen University
Phase 2
39
Guangzhou
2024-09-01
Recruiting
Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma
NCT06864221Hepatocellular Carcinoma, Radiotherapy, Treatment Outcome, Biomarkers
Nanfang Hospital, Southern Medical University
Observational
260
Guangzhou
2024-09-01
Recruiting
Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
NCT06581315Hepatocellular Carcinoma, Adjuvant Therapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
204
Guangzhou
2024-08-28
Active, closed
RenJi Hospital
Not applicable
12
Shanghai
2024-08-06
Recruiting
Shanghai Zhongshan Hospital
Observational
50
Shanghai
2024-08-01
Recruiting
RenJi Hospital
Not applicable
1,115
Shanghai
2024-08-01
Recruiting
Anhui Provincial Hospital
Phase 2
45
Fuyang, Hefei
2024-07-20
Recruiting
Nanfang Hospital, Southern Medical University
Observational
900
Guangzhou
2024-07-01
Recruiting
Lion TCR Pte. Ltd.
Phase 1
10
Beijing
2024-06-01
Not yet open
Tongji Hospital
Phase 3
360
Wuhan
2024-06-01
Recruiting
Shanghai Zhongshan Hospital
Observational
240
Shanghai
2024-05-15
Recruiting
Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
NCT06389422Hepatocellular Carcinoma, Radiotherapy, Pembrolizumab, Tumor Thrombosis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing
2024-05-01
Recruiting
Yongyi Zeng
Phase 2
33
Fuzhou
2024-04-22
Recruiting
Sun Yat-sen University
Phase 2
140
Guangzhou
2024-04-05
Not yet open
Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS
NCT06317896Hepatocellular Carcinoma, Circulating Tumor Cell, Recurrence, Surgery
Zhujiang Hospital
Observational
82
Foshan, Guangzhou
2024-04-01
Recruiting
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Phase 2
40
Fuzhou
2024-03-31
Recruiting
Peking Union Medical College Hospital
Phase 1
40
Beijing
2024-03-11
Recruiting
Mian XI
Phase 2
60
Guangzhou
2024-03-10
Recruiting
Immunotherapy for Hepatocellular Carcinoma
NCT06241326Hepatocellular Carcinoma, Immunotherapy
The First Affiliated Hospital with Nanjing Medical University
Observational
11,000
Nanjing
2024-03-01
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
600
Hangzhou
2024-02-05
Recruiting
Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
NCT06265350Hepatocellular Carcinoma, Liver Cancer Stage IV, Pulmonary Metastases, Cadonilimab
Sun Yat-sen University
Not applicable
80
Guanzhou
2024-02-02
Recruiting
Zhongda Hospital
Not applicable
5
Nanjing
2024-02-01
Not yet open
Harbin Medical University
Phase 2
36
Harbin
2024-01-31
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
100
Beijing
2024-01-26
Recruiting
Henan Cancer Hospital
Not applicable
22
Zhengzhou
2024-01-15
Recruiting
ITGA6 Targeting NIR-II Fluorescence Image Guided Surgery
NCT06204835Hepatocellular Carcinoma
Institute of Automation, Chinese Academy of Sciences
Phase 1
90
Guangzhou, Luzhou
2024-01-07
Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
38
Wuhan
2024-01-01
Recruiting
Zhongda Hospital
Not applicable
188
Beijing, Nanjing
2023-12-19
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
71
Xiamen
2023-11-15
Recruiting
AbbVie
Phase 1
325
2023-11-09
Recruiting
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
NCT06041477Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity
Sun Yat-sen University
Phase 3
540
Guangzhou
2023-10-31
Active, closed
Hoffmann-La Roche
Phase 3
687
Baoji, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou
2023-09-14
Not yet open
Qilu Pharmaceutical Co., Ltd.
Phase 2/3
668
Nanjing, Shanghai
2023-09-01
Recruiting
Guangdong Provincial People's Hospital
Phase 2
29
Guangzhou
2023-09-01
Recruiting
Sun Yat-sen University
Phase 2
43
Guangzhou
2023-09-01
Recruiting
TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
NCT05984511Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus
Third Affiliated Hospital, Sun Yat-Sen University
Not applicable
234
Guangzhou
2023-08-30
Recruiting
SIRT for Potentially Resectable HCC
NCT05994859Hepatocellular Carcinoma
Second Affiliated Hospital of Guangzhou Medical University
Not applicable
35
Guangzhou
2023-08-10
Recruiting
Zhejiang Cancer Hospital
Phase 2
35
Hangzhou
2023-07-01
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
59
Guangzhou
2023-06-21
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
480
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning
2023-05-10
Active, closed
AstraZeneca
Phase 2
294
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Harbin, Nanning, Shanghai
2023-04-24
Recruiting
Sun Yat-sen University
Phase 2
55
Guangzhou
2023-03-09
Not yet open
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
140
Hangzhou
2023-03-01
Active, closed
AstraZeneca
Phase 3
214
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan
2023-02-15
Recruiting
Beijing Hospital
Not applicable
88
Beijing
2023-02-01
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 3
130
Nanjing
2023-01-31
Recruiting
Akeso
Phase 3
570
Shanghai
2023-01-05
Recruiting
RenJi Hospital
Not applicable
12
Shanghai
2023-01-01
Active, closed
Tianjin Medical University Cancer Institute and Hospital
Not applicable
60
Tianjin
2022-12-20
Recruiting
OriCell Therapeutics Co., Ltd.
Phase 1/2
105
Beijing, Changsha, Changchun, Chengdu, Hangzhou, Lishui, Shanghai
2022-12-15
Active, closed
Shen Feng
Observational
122
Shanghai
2022-09-20
Recruiting
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Observational
300
Fuzhou
2022-08-20
Recruiting
Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
NCT05484908Immune-Mediated Hepatitis, Liver Failure, Hepatocellular Carcinoma
Third Affiliated Hospital, Sun Yat-Sen University
Not applicable
60
Guangzhou
2022-08-12
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
423
Shanghai
2022-08-09
Recruiting
Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
NCT05444478Hepatocellular Carcinoma, Microwave Ablation, Liver Cancer, Lenvatinib
Sun Yat-sen University
Not applicable
274
Changsha
2022-07-01
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Not applicable
100
Nanjing
2022-05-01
Recruiting
CT-guided Localization for Micro Hepatocellular Carcinoma Before Surgical Resection
NCT05433467Cirrhosis, Liver, Hepatocellular Carcinoma
Northern Jiangsu People's Hospital
Not applicable
5
Yangzhou
2022-05-01
Active, closed
AstraZeneca
Phase 3
760
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou
2022-03-28
Recruiting
Zhejiang University
Phase 1
72
Hangzhou, Zhengzhou
2022-02-21
Recruiting
The Affiliated Hospital of Xuzhou Medical University
Phase 1/2
15
Xuzhou
2022-02-10
Active, closed
Sun Yat-sen University
Phase 3
214
Guangzhou
2022-01-17
By invitation
Abbisko Therapeutics Co, Ltd
Phase 2
118
Hubei
2021-12-30
Recruiting
Xiangya Hospital of Central South University
Observational
360
Changsha
2021-12-01
Recruiting
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
NCT05024214Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
3D Medicines (Sichuan) Co., Ltd.
Phase 1/2
170
Bengbu, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Zhuhai, Haerbin
2021-11-15
Recruiting
Chinese Academy of Sciences
Not applicable
60
Zhuhai, Luzhou
2021-09-10
Recruiting
Guangxi Medical University
Phase 2/3
62
Nanning
2021-06-01
Active, closed
Shanghai Zhongshan Hospital
Phase 2/3
294
Shanghai
2021-03-25
Active, closed
Hoffmann-La Roche
Phase 3
342
Anhui, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2021-03-12
Recruiting
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
50
Guangzhou
2021-03-01
Recruiting
Sun Yat-sen University
Not applicable
320
Guangzhou
2021-02-20
Recruiting
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
NCT06333561Hepatocellular Carcinoma, Lenvatinib, PD-1 Inhibitor, Hepatic Arterial Infusion Chemotherapy
Sun Yat-sen University
Observational
300
Beijing
2021-01-01
Recruiting
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
100
Guangzhou
2021-01-01
Active, closed
Peking Union Medical College Hospital
Observational
180
Beijing
2020-12-06
Recruiting
Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs
NCT04770207Hepatocellular Carcinoma, Solid Tumor, Adult
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
100
Guangzhou
2020-11-01
By invitation
Fujian Provincial Hospital
Observational
35
Fuzhou
2020-11-01
Recruiting
Tongji Hospital
Observational
200
Wuhan
2020-05-01
Recruiting
Chinese PLA General Hospital
Not applicable
1,134
Beijing
2019-12-26
Active, closed
CStone Pharmaceuticals
Phase 3
534
Bengbu, Hefei, Beijing, Fuzhou, Xiamen, Foshan, Guangzhou, Nanning
2019-12-13
Active, closed
Chen Xiaoping
Not applicable
1,076
Wuhan
2019-12-01
Active, closed
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
NCT06239155Advanced Solid Tumors, Hepatocellular Carcinoma
Ascentawits Pharmaceuticals, Ltd
Phase 1/2
51
Guangzhou, Zhengzhou, Nanjing, Shenyang, Shanghai, Hangzhou
2019-09-03
Recruiting
Personalized DC Vaccine for Postoperative Cancer
NCT04147078Gastric Cancer, Hepatocellular Carcinoma, Non-Small-Cell Lung Cancer, Colon Rectal Cancer
Sichuan University
Phase 1
80
Chengdu
2019-06-01
Active, closed
Sun Yat-sen University
Phase 2
40
Guangzhou
2019-03-25
Active, closed
Shanghai Junshi Bioscience Co., Ltd.
Phase 2/3
427
Shanghai
2019-03-05
Recruiting
Guangxi Medical University
Observational
10,000
Nanning
2019-03-03
Recruiting
Guangxi Medical University
Observational
2,000
Nanning
2019-01-01
Active, closed
AstraZeneca
Phase 3
724
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2018-11-30
Recruiting
Humanity & Health Medical Group Limited
Observational
5,000
Beijing
2018-07-16
Active, closed
Exelixis
Phase 3
837
Hefei, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2018-06-10
Active, closed
AstraZeneca
Phase 3
1,324
Beijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Guangzhou, Hangzhou
2017-10-11
Recruiting
GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
NCT03198546Hepatocellular Carcinoma, Immunotherapy, CAR, GPC3 Gene Inactivation
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
30
Guangzhou
2017-07-01
Recruiting
Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
NCT03093688Non-small Cell Lung Cancer, Small Cell Lung Cancer, Pancreas Cancer, Hepatocellular Carcinoma
Shanghai Public Health Clinical Center
Phase 1/2
40
Shanghai
2017-03-01
Active, closed
MedImmune LLC
Phase 2
433
Hangzhou, Nanjing, Shanghai
2015-10-19
Recruiting
Chinese PLA General Hospital
Phase 2/3
80
Beijing
2009-12
Rows per page Showing 1–154 of 154
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 November 2026. https://priyalifescience.com/clinical-trials-china/condition/hepatocellular-carcinoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 07 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 154 of those studies listing the condition Hepatocellular Carcinoma.

How many Hepatocellular Carcinoma trials are recruiting in China?

101 of the 154 studies on this page are recruiting new participants as of the 07 Nov 2026, 03:17 UTC sync. A further 23 have not yet opened recruitment, 27 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hepatocellular Carcinoma), 154 studies
PhaseStudiesRecruitingShare
Phase 2372524%
Observational312020.1%
Not applicable302419.5%
Phase 3251016.2%
Phase 114129.1%
Phase 1/21086.5%
Phase 2/3623.9%
Early Phase 1100.6%

Most active sponsors

Lead sponsors with the most studies (Hepatocellular Carcinoma)
Lead sponsorStudiesRecruiting
Sun Yat-sen University2018
AstraZeneca82
Second Affiliated Hospital of Guangzhou Medical University65
Guangxi Medical University54
Chinese PLA General Hospital43
The First Affiliated Hospital with Nanjing Medical University43
AbbVie31
Akeso33
Fujian Provincial Hospital31
Peking Union Medical College Hospital32
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.